In a Spanish Lung Cancer Group ( SLCG ) phase II trial , the combination of BRCA@ and receptor-associated protein @ ( RAP@ ) expression was significantly associated with outcome in Caucasian patients with nonsmall-cell lung cancer ( NSCLC ) .